Goossens H
Department of Microbiology, University Hospital Antwerp, Edegem-Antwerp, Belgium.
Infect Control Hosp Epidemiol. 1998 Aug;19(8):546-51. doi: 10.1086/647871.
There are major differences in the epidemiology of vancomycin-resistant enterococci (VRE) between the United States and Europe. In contrast with Europe, VRE in the United States are resistant to many antibiotics, and there appears to be less genetic variability among these isolates. European VRE of human origin are usually susceptible to many other antibiotics and are highly polyclonal. These clinical isolates have the same susceptibility profiles as VRE isolated from animals. The differences in the spread of VRE between the United States and Europe might be explained by the overconsumption of glycopeptides and other antibiotics in hospitals in the United States and the use of avoparcin as a growth promotor in Europe.
美国和欧洲在耐万古霉素肠球菌（VRE）的流行病学方面存在重大差异。与欧洲不同，美国的VRE对多种抗生素耐药，而且这些分离株之间的遗传变异性似乎较小。源自人类的欧洲VRE通常对许多其他抗生素敏感，并且是高度多克隆的。这些临床分离株与从动物中分离出的VRE具有相同的药敏谱。美国和欧洲VRE传播情况的差异可能是由美国医院中糖肽类和其他抗生素的过度使用以及欧洲将阿伏帕星用作生长促进剂所导致的。
